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Hepatitis E virus (HEV) is transfusion-transmissible and therefore poses a risk to blood transfusion safety. Seroprevalence
studies are useful for estimating disease burden and determining risk factors. Considerable variability in the sensitivity of HEV
antibody detection assays exists. This study aimed to compare the performances of commercially available HEV enzyme-linked
immunosorbent assays (ELISA) in Australian blood donor samples. Plasma samples that tested positive (𝑛 = 194) or negative
(𝑛 = 200) for HEV IgG (Wantai HEV IgG ELISA) were selected. Of the 194 HEV IgG positive samples, 4 were positive for HEV
IgM (Wantai HEV IgM ELISA). All samples were tested with the MP Diagnostics: HEV IgG ELISA, total (IgG, IgM, and IgA)
HEV antibody ELISA, and HEV IgM ELISA. Of the 194 Wantai HEV IgG positive samples, 92 (47%) tested positive with the MP
Diagnostics HEV IgG ELISA (𝜅 = 0.47) and 126 (65%) with MP Diagnostics total HEV antibody assay (𝜅 = 0.65). There was
poor agreement between Wantai and MP Diagnostics HEV IgM assays. This study demonstrated poor agreement between the
assays tested. These observations are consistent with previous reports demonstrating significant variability between HEV ELISAs,
highlighting that results of HEV serology should be interpreted with caution.
1. Introduction
Hepatitis E virus (HEV) is a nonenveloped, RNA virus,
classified in the genus Hepevirus of the Hepeviridae family
[1].There are 4 genotypes of HEV [1–4], representing a single
serotype, which infect humans [2]. This classification into
genotypes is based on variation in the nucleotides within
open reading frame-2 (ORF-2) [3, 4]. HEVwas first observed
under immune electron microscopy in stool samples from a
volunteer experimentally infected with non-A, non-B hep-
atitis [5]. Isolation of cDNA identified this virus as being
different from hepatitis A [6] and facilitated the development
of serological assays for HEV.
HEV causes self-limited acute phase disease with known
cases of chronic hepatitis [7]. The incubation period on aver-
age is 40 days [8]. Clinical features include anorexia, nausea,
vomiting, diarrhoea, epigastric pain, fever, jaundice, eleva-
tion of serum transaminase, and hepatomegaly [5, 7, 9–11].
Chronic HEV infections have been reported in solid-organ
transplant recipients [12] and in immune suppressive condi-
tions [13, 14]. A case fatality rate of 0.5–4% has been reported
in developing countries [7], which is as high as 10–25% in
pregnant women during the third trimester [2, 15, 16].
HEV is transfusion-transmissible and causes chronic
infections in immunocompromised individuals [17].The risk
of transfusion-transmission from a donorwith asymptomatic
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viraemia can be identified through the detection of HEV
RNA. However, the detection of HEV antibodies provides
useful information on the immune status or stages of HEV
infection in blood donors and may assist with the identi-
fication of risk factors for exposure. Seroprevalence is also
important for assessing the overall disease burden in a pop-
ulation, and studies have shown that HEV exposure in blood
donors varies widely between geographical regions [18, 19].
For example, 6%ofAustralian blood donors have been shown
to be HEV IgG positive, while 52% of donors in southwestern
France were HEV IgG positive with the same assay [20, 21].
Serology-based HEV tests for the detection of viral-
specific antibodies include the detection of HEV IgG, HEV
IgM, and HEV IgA in serum or plasma. Antibody testing
assays are generally based on the detection of antibodies
against epitopes of the gene products from ORF2 and ORF3
[22]. Many enzyme immunoassays with antigens derived
from one HEV genotype are able to detect antibodies against
a different genotype [23]. Detection of HEV IgG in an
individual indicates a previous HEV infection.This antibody
may persist in an infected individual for more than 12 years
[24].The acute phase of HEV infection can be detected by the
detection of HEV IgM. This class of antibody is detectable
after the onset of acute hepatitis and can last for up to 6
months following infection [25].
Studies with different commercial HEV IgG enzyme
immunoassays have shown variability in sensitivity [26–28].
A study using anti-HEV reference serum (from the World
Health Organisation) and including known HEV cases has
shown 98% seropositivity with the Wantai IgG assay com-
pared to 56% with the Genelabs IgG assay [27]. In a Korean
study, HEV IgG seroprevalence was measured to be 23.1%
with the Wantai assay, compared to 14.3% with the Genelabs
assay [29]. Moreover, a study in HEV infected individuals
has shown positivity of 83.3%, 100%, and 96.7% with the MP
Diagnostics assay, Axiom Diagnostics assay (developed by
Wantai), and Mikrogen assay, respectively [30]. Seropreva-
lence determined with different assays therefore needs to be
interpretedwith caution. Evaluation ofHEV IgMcommercial
assays has also shown variability in sensitivity and specificity
[31]. Given the importance of reliable seroprevalence esti-
mates, this study aimed to compare the performances of
commercially available HEV antibody detection assays (IgG
and/or IgM) using a panel of Australian blood donor samples,
made up of preselected positive and negative samples by one
widely used assay.
2. Materials and Methods
2.1. Samples. Plasma samples from individual donors (𝑛 =
394) selected from a previous HEV seroprevalence study [20]
were included in this study.These included samples (𝑛 = 194)
that tested positive for HEV IgG with the Wantai HEV IgG
ELISA (BeijingWantai Biological Pharmacy, Beijing, China).
These positive samples were all of the HEV IgG positive
samples obtained from the previous seroprevalence study,
which included 3,237 donors randomly selected for sex and
age group [20]. Of the HEV IgG positive samples, 4 were
also positive for HEV IgM with Wantai HEV IgM ELISA. In
addition, age-matched negative samples (𝑛 = 200) were also
sourced from the same seroprevalence study. Blood samples
were collected in EDTA tubes (BD VacutainerWhole Blood
Collection tube with spray-coated K2EDTA 6mL, Becton
Dickinson, Plymouth, UK), centrifuged at 1,258 g for 5 min-
utes and stored at −20∘C until testing. Convenience samples
no longer required after routine viral screening were utilised
for this study and all samples were collected between August
and September, 2013.The age of the donor was obtained from
Blood Service records. This study was approved by Blood
Service Human Research Ethics Committee.
2.2. Sample Testing:Wantai HEV ELISAs. The above-selected
samples were tested for HEV IgG with the Wantai HEV
IgG ELISA (Beijing Wantai Biological Pharmacy Enterprise
Co., Ltd.). Samples reactive for HEV IgG were tested for
HEV IgM with the Wantai HEV IgM ELISA (Beijing Wantai
Biological Pharmacy Enterprise Co., Ltd.). Samples were
tested as per the manufacturer’s instructions and absorbance
was measured using a Hybrid Multimode Microplate Reader
(BioTek Instruments, Inc., Winooski, USA) at 450 nm. Sam-
ples initially reactive for HEV IgG or HEV IgM were retested
in duplicate with the respective assay and considered positive
if reactive at least twice. After testing, samples were aliquoted
into microtubes (Axygen Inc., USA) and stored at −20∘C
prior to testing with secondary commercial assays.
The Wantai HEV IgG assay is based on a recombinant
HEVPE2protein containing 211 amino acids ofORF2 derived
from HEV genotype 1 [26, 27]. Sensitivity and specificity of
the HEV IgG assay have been shown to be 97.96% and 99.6%,
respectively [32, 33].TheWantai HEV IgM assay is also based
on a recombinant protein derived from HEV ORF2 [34].
Sensitivity of HEV IgM assay has been shown to be 97.10%
[34]. Both the assays required 10 𝜇L of sample, which was
diluted with diluent (1 : 11) [32, 34].
2.3. Sample Testing: MP Diagnostics ELISAs. The above-
selected samples were tested in singlet for HEV IgG with the
MP Diagnostics HEV ELISA (MP Biomedicals Asia Pacific,
Singapore), total (IgG, IgM, and IgA) HEV antibody with
the MP Diagnostics HEV ELISA 4.0 (MP Biomedicals); and
HEV IgMwith theMPDiagnostics HEV IgM ELISA 3.0 (MP
Biomedicals). Samples were tested as per the manufacturer’s
instructions and absorbance was measured using a Hybrid
Multimode Microplate Reader (BioTek Instruments, Inc.)
at 450 nm. Samples initially reactive with each assay were
retested in duplicate with the same assay and considered
positive if reactive at least two out of three times.
The MP Diagnostics HEV IgG assay uses three recombi-
nant proteins, consisting of 42-amino acid sequence derived
from ORF2 of genotype 2, 33-amino acid sequence from
ORF3 of genotype 3, and ORF3 sequence from genotype 1
[26]. The assay has a reported sensitivity of 98% and specific-
ity of 97% [35]. The assay required 10 𝜇L of sample and was
diluted with diluent (1 : 21).
MP Diagnostic HEV ELISA 4.0 detects IgG, IgM, and
IgA antibodies.The assay uses highly conservedHEVORF2.1
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Table 1: Comparison of test results between the Wantai HEV IgG
ELISA and MP Diagnostics HEV ELISA (IgG).
Wantai (HEV IgG) MP Diagnostics (HEV IgG) Total
Positive Negative
Positive 92 (47.4%) 102 194
Negative 1 199 (99.5%) 200
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Figure 1: S/Co Wantai HEV IgG versus MP Diagnostics HEV IgG.
antigen, which is able to detect all antibody isotypes [36].The
test required 20 𝜇L of sample and was diluted with diluent
(1 : 50). The assay has a reported sensitivity of 99.2% and
specificity of 99.2% [35].
MP Diagnostic HEV IgM ELISA is based on genotype 1
and 2 antigens derived from ORF2 and ORF3 [37]. The assay
has a reported sensitivity of 98% and specificity of 96.7% [35].
The assay used 10 𝜇L of sample and was diluted with diluent
(1 : 21).
2.4. Data Analysis. Sample to cut-off ratio was calculated,
and results were interpreted based on criteria from the
manufacturers’ instructions. Concordance between assays
was determined by calculating Kappa (𝜅) correlation, which
measures the agreement between two assays, using IBM SPSS
Statistics 23 (IBM Centre, NSW, Australia).
3. Results
Of the 194WantaiHEV IgG reactive samples, 92 were reactive
with the MP Diagnostics HEV IgG ELISA. One of the 200
negative samples with the Wantai HEV IgG assay tested
positive with MP Diagnostics HEV IgG ELISA. There was
a poor agreement between these assays (𝜅 = 0.47) (Table 1,
Figure 1). However, the agreement between MP Diagnostics
total HEV antibody assay and Wantai HEV IgG was higher
(𝜅 = 0.65) with 126/194 testing positive (Table 2, Figure 2).
All the Wantai HEV IgG negative samples were also negative
with MP Diagnostics total HEV antibody assay. Of the 4
Wantai HEV IgM positive samples, none tested positive for
HEV IgM on the MP Diagnostics HEV IgM ELISA (Table 3).
Table 2: Comparison of test results between the Wantai HEV IgG
ELISA and MP Diagnostics HEV ELISA 4.0 (IgG, IgM, and IgA).
Wantai
(HEV IgG)
MP Diagnostics (HEV IgG, IgM, and IgA) Total
Positive Negative
Positive 126 (64.94%) 68 194
Negative 0 200 (100%) 200
Total 126 268 394
Table 3: Comparison of test results between the Wantai HEV IgM
ELISA and MP Diagnostics HEV IgM ELISA 3.0.
Wantai
(HEV IgM)
MP Diagnostics (HEV IgM) Total
Positive Negative
Positive 0 4 4
Negative 5 385 (98.7%) 390
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Figure 2: S/Co Wantai HEV IgG versus MP Diagnostics HEV
ELISA 4.0 (IgG, IgM, and IgA).
All Wantai HEV IgM positive samples were positive with MP
Diagnostics total HEV antibody assay.
Comparing the test results between the MP Diagnostics
total HEV antibody ELISA and MP Diagnostics HEV IgG
ELISA, 82 of 126 (88.17%) tested positive with the latter (𝜅 =
0.65). However, 11 of the samples that tested negative withMP
Diagnostics total HEV antibody ELISA were positive with
MPDiagnosticsHEV IgGELISA (Table 4, Figure 3).Of these,
10 samples were positive with Wantai HEV IgG ELISA.
4. Discussion
HEV is a causative agent of acute hepatitis. The majority of
HEV cases in developed countries are in travellers returning
from developing countries endemic for HEV [25]; however,
autochthonous HEV related to zoonotic transmission [2] and
transfusion-transmission [17] have also been reported. HEV
serological assays have allowed seroprevalence studies, which
provide useful surveillance data on the distribution of this
virus, and have also assisted with identifying risk factors for
exposure to HEV. However, studies have shown variability in
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Table 4: Comparison of test results between the MP Diagnostics




MP Diagnostics (HEV IgG, IgM, and IgA) Total
Positive Negative
Positive 82 (88.17%) 11 93
Negative 44 257 (85.38%) 301
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Figure 3: S/Co MP Diagnostics HEV IgG versus MP Diagnostics
HEV ELISA 4.0 (IgG, IgM, and IgA).
estimates with different commercial assays [21, 28], and the
results presented herein are consistent with such findings.
In this study, a poor concordance of test results between
the two tested commercial HEV IgG ELISAs was observed.
Only 47% (92/194) ofWantai HEV IgG positive samples were
positive with the MP Diagnostics HEV IgG (𝜅 = 0.47). This
observation is similar to aKorean study, which also compared
Wantai and Genelabs (nowMPDiagnostics) HEV IgG assays
(𝜅 = 0.31) [29]. One of the samples negative with Wantai
HEV IgG assay was positive with the MP Diagnostic HEV
IgG assay (0.50%), similar to an observation in a French study
(0.69%) using a Fortress Diagnostics assay that uses Wantai
recombinant proteins [26]. Previous studies have shown that
the Wantai HEV IgG ELISA is one of the most sensitive
commercial assays available for the detection of HEV IgG
[27, 29, 30].
Our study also showed a higher agreement between the
Wantai HEV IgG and MP Diagnostic HEV total antibody
assay (𝜅 = 0.65). The total antibody ELISA is more recently
developed (compared to the MP Diagnostics HEV IgG
assay) incorporating an improved antigen with the ability to
detect total antibodies (IgG, IgM, and IgA) against all HEV
genotypes [36]. It is possible that the Wantai HEV IgG could
have given nonspecific results, but the majority of Wantai
HEV IgG negative samples still tested negative with the MP
Diagnostic HEV IgG assay (199 of 200). In addition, there
was also nonconcordance between MP Diagnostic total and
IgG assays. The proportion of samples positive with the MP
Diagnostics IgG assay compared to the proportion positive
with the MP Diagnostics total assay was unexpected (88%)
and therefore questions the performance of the IgG assay
assuming that the samples represented true positives.
Comparison of theWantai HEV IgM andMPDiagnostics
HEV IgM assays also showed poor agreement between these
assays. A prior study has shown good specificity of the MP
Diagnostic HEV IgM assay (99.5%) [37]. However, in our
study, oneHEV IgMpositive sample with theMPDiagnostics
HEV IgM assay was negative with MP Diagnostic total anti-
body assay. All four samples positive with Wantai HEV IgM
assay were also positive with MP Diagnostic total antibody
assay, demonstrating agreement between these assays.
The observed variability in assay performance could
be explained by differences in recombinant proteins, assay
formats, or other components (e.g., diluents) used in each
assay, as well as sample selection given they were primar-
ily preselected Wantai IgG-positive. Additional studies are
required to elucidate the exact mechanism; however, it is
clear that a “gold standard” for HEV antibody detection is
desperately needed. The validity of serological assays for use
in a particular study should be assessed prior to their use,
and control samples from individuals diagnosed with HEV
should be included wherever possible. Given that neither the
infection history nor the exact serostatus (positive or negative
based on confirmatory assays) of the samples was known,
sensitivity and specificity of these assays could not be assessed
in the present study. Thus, the findings of this study should
be interpreted considering this limitation. Further studies
including pedigreed seropositive/negative samples or those
from individuals with a known history of HEV infection are
clearly required.
5. Conclusion
In this study, a poor concordance of test results between
the Wantai and MP Diagnostics HEV ELISAs was observed.
Variability in results was likely due to differences in antigens,
assay format, or other components used in each assay, as well
as the fact that assumed seropositive samples were primarily
preselectedWantai IgG-positive samples. These observations
are consistent with previous reports demonstrating signifi-
cant variability between HEV ELISAs, highlighting that due
caution is required when interpreting the results of HEV
serology.There is still a need for the development of sensitive,
specific, and cost-effective HEV antibody assays, including
confirmatory tests, to aid in estimating disease burden and
determining risk factors for HEV exposure.
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